BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1124 related articles for article (PubMed ID: 19479852)

  • 1. Neutralization of interferon-alpha/beta-inducible genes and downstream effect in a phase I trial of an anti-interferon-alpha monoclonal antibody in systemic lupus erythematosus.
    Yao Y; Richman L; Higgs BW; Morehouse CA; de los Reyes M; Brohawn P; Zhang J; White B; Coyle AJ; Kiener PA; Jallal B
    Arthritis Rheum; 2009 Jun; 60(6):1785-96. PubMed ID: 19479852
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety profile and clinical activity of sifalimumab, a fully human anti-interferon α monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study.
    Merrill JT; Wallace DJ; Petri M; Kirou KA; Yao Y; White WI; Robbie G; Levin R; Berney SM; Chindalore V; Olsen N; Richman L; Le C; Jallal B; White B;
    Ann Rheum Dis; 2011 Nov; 70(11):1905-13. PubMed ID: 21798883
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of type I interferon-inducible mRNAs as pharmacodynamic markers and potential diagnostic markers in trials with sifalimumab, an anti-IFNα antibody, in systemic lupus erythematosus.
    Yao Y; Higgs BW; Richman L; White B; Jallal B
    Arthritis Res Ther; 2010; 12 Suppl 1(Suppl 1):S6. PubMed ID: 20392292
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-interferon alpha treatment in SLE.
    Kirou KA; Gkrouzman E
    Clin Immunol; 2013 Sep; 148(3):303-12. PubMed ID: 23566912
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regulation of the interferon-alpha production induced by RNA-containing immune complexes in plasmacytoid dendritic cells.
    Eloranta ML; Lövgren T; Finke D; Mathsson L; Rönnelid J; Kastner B; Alm GV; Rönnblom L
    Arthritis Rheum; 2009 Aug; 60(8):2418-27. PubMed ID: 19644885
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activation of the interferon-alpha pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease.
    Kirou KA; Lee C; George S; Louca K; Peterson MG; Crow MK
    Arthritis Rheum; 2005 May; 52(5):1491-503. PubMed ID: 15880830
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Coordinate overexpression of interferon-alpha-induced genes in systemic lupus erythematosus.
    Kirou KA; Lee C; George S; Louca K; Papagiannis IG; Peterson MG; Ly N; Woodward RN; Fry KE; Lau AY; Prentice JG; Wohlgemuth JG; Crow MK
    Arthritis Rheum; 2004 Dec; 50(12):3958-67. PubMed ID: 15593221
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Decreased production of interleukin-12 and other Th1-type cytokines in patients with recent-onset systemic lupus erythematosus.
    Horwitz DA; Gray JD; Behrendsen SC; Kubin M; Rengaraju M; Ohtsuka K; Trinchieri G
    Arthritis Rheum; 1998 May; 41(5):838-44. PubMed ID: 9588735
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interferon-alpha mediates suppression of C-reactive protein: explanation for muted C-reactive protein response in lupus flares?
    Enocsson H; Sjöwall C; Skogh T; Eloranta ML; Rönnblom L; Wetterö J
    Arthritis Rheum; 2009 Dec; 60(12):3755-60. PubMed ID: 19950271
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The influence of antimalarial treatment on IL-1beta, IL-6 and TNF-alpha mRNA expression on UVB-irradiated skin in systemic lupus erythematosus.
    Wozniacka A; Lesiak A; Boncela J; Smolarczyk K; McCauliffe DP; Sysa-Jedrzejowska A
    Br J Dermatol; 2008 Nov; 159(5):1124-30. PubMed ID: 18764842
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Down-regulation of interferon signature in systemic lupus erythematosus patients by active immunization with interferon α-kinoid.
    Lauwerys BR; Hachulla E; Spertini F; Lazaro E; Jorgensen C; Mariette X; Haelterman E; Grouard-Vogel G; Fanget B; Dhellin O; Vandepapelière P; Houssiau FA
    Arthritis Rheum; 2013 Feb; 65(2):447-56. PubMed ID: 23203821
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of activated cytokine pathways in the blood of systemic lupus erythematosus, myositis, rheumatoid arthritis, and scleroderma patients.
    Higgs BW; Zhu W; Richman L; Fiorentino DF; Greenberg SA; Jallal B; Yao Y
    Int J Rheum Dis; 2012 Feb; 15(1):25-35. PubMed ID: 22324944
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of functional interleukin 10/tumor necrosis factor-alpha polymorphisms on interferon-alpha, IL-10, and regulatory T cell population in patients with systemic lupus erythematosus receiving antimalarial treatment.
    López P; Gómez J; Prado C; Gutiérrez C; Suárez A
    J Rheumatol; 2008 Aug; 35(8):1559-66. PubMed ID: 18597405
    [TBL] [Abstract][Full Text] [Related]  

  • 14. C1q inhibits immune complex-induced interferon-alpha production in plasmacytoid dendritic cells: a novel link between C1q deficiency and systemic lupus erythematosus pathogenesis.
    Lood C; Gullstrand B; Truedsson L; Olin AI; Alm GV; Rönnblom L; Sturfelt G; Eloranta ML; Bengtsson AA
    Arthritis Rheum; 2009 Oct; 60(10):3081-90. PubMed ID: 19790049
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of the markers BDCA-2 and BDCA-4 and production of interferon-alpha by plasmacytoid dendritic cells in systemic lupus erythematosus.
    Blomberg S; Eloranta ML; Magnusson M; Alm GV; Rönnblom L
    Arthritis Rheum; 2003 Sep; 48(9):2524-32. PubMed ID: 13130472
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of B-cell activating factor of the tumour necrosis factor family (BAFF) in T cells in active systemic lupus erythematosus: the role of BAFF in T cell-dependent B cell pathogenic autoantibody production.
    Morimoto S; Nakano S; Watanabe T; Tamayama Y; Mitsuo A; Nakiri Y; Suzuki J; Nozawa K; Amano H; Tokano Y; Kobata T; Takasaki Y
    Rheumatology (Oxford); 2007 Jul; 46(7):1083-6. PubMed ID: 17500077
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interferon-α priming promotes lipid uptake and macrophage-derived foam cell formation: a novel link between interferon-α and atherosclerosis in lupus.
    Li J; Fu Q; Cui H; Qu B; Pan W; Shen N; Bao C
    Arthritis Rheum; 2011 Feb; 63(2):492-502. PubMed ID: 21280004
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lack of association between the interferon-alpha signature and longitudinal changes in disease activity in systemic lupus erythematosus.
    Landolt-Marticorena C; Bonventi G; Lubovich A; Ferguson C; Unnithan T; Su J; Gladman DD; Urowitz M; Fortin PR; Wither J
    Ann Rheum Dis; 2009 Sep; 68(9):1440-6. PubMed ID: 18772188
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytokine polymorphisms influence treatment outcomes in SLE patients treated with antimalarial drugs.
    López P; Gómez J; Mozo L; Gutiérrez C; Suárez A
    Arthritis Res Ther; 2006; 8(2):R42. PubMed ID: 16507146
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aberrant expression of BAFF in T cells of systemic lupus erythematosus, which is recapitulated by a human T cell line, Loucy.
    Yoshimoto K; Takahashi Y; Ogasawara M; Setoyama Y; Suzuki K; Tsuzaka K; Abe T; Takeuchi T
    Int Immunol; 2006 Jul; 18(7):1189-96. PubMed ID: 16740602
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 57.